KR102015355B1 - 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 - Google Patents

전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 Download PDF

Info

Publication number
KR102015355B1
KR102015355B1 KR1020180069590A KR20180069590A KR102015355B1 KR 102015355 B1 KR102015355 B1 KR 102015355B1 KR 1020180069590 A KR1020180069590 A KR 1020180069590A KR 20180069590 A KR20180069590 A KR 20180069590A KR 102015355 B1 KR102015355 B1 KR 102015355B1
Authority
KR
South Korea
Prior art keywords
compound
added
prostate cancer
dissolved
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180069590A
Other languages
English (en)
Korean (ko)
Other versions
KR20180138169A (ko
Inventor
지대윤
이병세
추소영
김민환
정운정
문희정
정현진
양성욱
이교철
이용진
박지애
김미현
유란지
임상무
Original Assignee
(주)퓨쳐켐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MYPI2019007226A priority Critical patent/MY195426A/en
Priority to AU2018288907A priority patent/AU2018288907B2/en
Priority to BR112019027183-0A priority patent/BR112019027183B1/pt
Priority to JP2019571446A priority patent/JP6913968B2/ja
Priority to MX2019015616A priority patent/MX388833B/es
Priority to CA3067696A priority patent/CA3067696C/en
Priority to EA202090071A priority patent/EA037781B1/ru
Priority to SG11201911602RA priority patent/SG11201911602RA/en
Priority to PCT/KR2018/006869 priority patent/WO2018236115A1/ko
Application filed by (주)퓨쳐켐 filed Critical (주)퓨쳐켐
Priority to US16/622,518 priority patent/US10870629B2/en
Publication of KR20180138169A publication Critical patent/KR20180138169A/ko
Application granted granted Critical
Publication of KR102015355B1 publication Critical patent/KR102015355B1/ko
Priority to PH12019502665A priority patent/PH12019502665A1/en
Priority to CL2019003727A priority patent/CL2019003727A1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020180069590A 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 Active KR102015355B1 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR112019027183-0A BR112019027183B1 (pt) 2017-06-19 2018-06-18 Composição farmacêutica para tratar ou diagnosticar câncer de próstata, radiofármaco para diagnóstico por imageamento de câncer de próstata
JP2019571446A JP6913968B2 (ja) 2017-06-19 2018-06-18 前立腺がんの診断のための１８ｆ標識化合物およびその使用
MX2019015616A MX388833B (es) 2017-06-19 2018-06-18 Compuesto marcado con 18f para diagnostico de cancer de prostata y uso de este
CA3067696A CA3067696C (en) 2017-06-19 2018-06-18 18f-labelled compound for prostate cancer diagnosis, and use thereof
EA202090071A EA037781B1 (ru) 2017-06-19 2018-06-18 18f-меченое соединение для диагностики рака предстательной железы и его применение
SG11201911602RA SG11201911602RA (en) 2017-06-19 2018-06-18 18f-labelled compound for prostate cancer diagnosis, and use thereof
MYPI2019007226A MY195426A (en) 2017-06-19 2018-06-18 18f-Labelled Compound for Prostate Cancer Diagnosis, and use Thereof
US16/622,518 US10870629B2 (en) 2017-06-19 2018-06-18 18F-labelled compound for prostate cancer diagnosis, and use thereof
AU2018288907A AU2018288907B2 (en) 2017-06-19 2018-06-18 18F-labelled compound for prostate cancer diagnosis, and use thereof
PCT/KR2018/006869 WO2018236115A1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
PH12019502665A PH12019502665A1 (en) 2017-06-19 2019-11-26 18f-labelled compound for prostate cancer diagnosis, and use thereof
CL2019003727A CL2019003727A1 (es) 2017-06-19 2019-12-18 Compuesto marcado con 18f para el diagnóstico de cáncer de próstata y uso de este.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170077570 2017-06-19
KR20170077570 2017-06-19

Publications (2)

Publication Number Publication Date
KR20180138169A KR20180138169A (ko) 2018-12-28
KR102015355B1 true KR102015355B1 (ko) 2019-10-23

Family

ID=65008286

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180069590A Active KR102015355B1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도

Country Status (21)

Country Link
US (1) US10870629B2 (https=)
EP (1) EP3643707B1 (https=)
JP (1) JP6913968B2 (https=)
KR (1) KR102015355B1 (https=)
CN (1) CN110770212B (https=)
AU (1) AU2018288907B2 (https=)
CA (1) CA3067696C (https=)
CL (1) CL2019003727A1 (https=)
DK (1) DK3643707T3 (https=)
EA (1) EA037781B1 (https=)
ES (1) ES2912392T3 (https=)
HR (1) HRP20220557T1 (https=)
LT (1) LT3643707T (https=)
MX (1) MX388833B (https=)
MY (1) MY195426A (https=)
PH (1) PH12019502665A1 (https=)
PL (1) PL3643707T3 (https=)
PT (1) PT3643707T (https=)
RS (1) RS63205B1 (https=)
SG (1) SG11201911602RA (https=)
SI (1) SI3643707T1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027870A1 (en) 2015-08-13 2017-02-16 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and "reversed" carbamates for psma-targeted imaging agents and uses thereof
US20170369454A1 (en) 2016-06-28 2017-12-28 Cornell University 18f-labeled triazole containing psma inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494096C2 (ru) 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
JP2014051442A (ja) * 2012-09-05 2014-03-20 Kyoto Univ 前立腺がんを診断可能な核医学イメージングプローブ
EP3300746B1 (en) * 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
ES3005832T3 (en) 2013-11-13 2025-03-17 Ge Healthcare Ltd Dual run cassette for the synthesis of 18f-labelled compounds
KR20150113801A (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 Tak1 저해 활성을 갖는 피라진 접합고리 유도체
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027870A1 (en) 2015-08-13 2017-02-16 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and "reversed" carbamates for psma-targeted imaging agents and uses thereof
US20170369454A1 (en) 2016-06-28 2017-12-28 Cornell University 18f-labeled triazole containing psma inhibitors

Also Published As

Publication number Publication date
CN110770212B (zh) 2022-11-22
DK3643707T3 (da) 2022-05-09
JP2020524175A (ja) 2020-08-13
EP3643707A4 (en) 2021-06-09
RS63205B1 (sr) 2022-06-30
US10870629B2 (en) 2020-12-22
PT3643707T (pt) 2022-05-04
CA3067696A1 (en) 2018-12-27
EA202090071A1 (ru) 2020-04-16
AU2018288907B2 (en) 2020-05-07
AU2018288907A1 (en) 2020-01-23
SI3643707T1 (sl) 2022-06-30
CA3067696C (en) 2022-05-03
HRP20220557T1 (hr) 2022-06-10
CL2019003727A1 (es) 2020-07-03
EP3643707B1 (en) 2022-02-23
US20200207724A1 (en) 2020-07-02
CN110770212A (zh) 2020-02-07
SG11201911602RA (en) 2020-01-30
KR20180138169A (ko) 2018-12-28
MY195426A (en) 2023-01-20
EA037781B1 (ru) 2021-05-20
MX388833B (es) 2025-03-12
PH12019502665A1 (en) 2020-10-26
ES2912392T3 (es) 2022-05-25
BR112019027183A2 (pt) 2020-06-30
PL3643707T3 (pl) 2023-06-12
EP3643707A1 (en) 2020-04-29
LT3643707T (lt) 2022-05-25
JP6913968B2 (ja) 2021-08-04
MX2019015616A (es) 2020-02-26

Similar Documents

Publication Publication Date Title
JP7036774B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
KR102233726B1 (ko) 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
US10201625B2 (en) Radiolabelled octreotate analogues as PET tracers
EP3375787B1 (en) Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer
CN111741751A (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
CN114796528B (zh) 肿瘤特异性靶向的多肽及其应用
EP3209336A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2007003019A (es) Compuestos de diagnostico.
US8629299B2 (en) Radiofluorinated compounds and their preparation
Wang et al. Synthesis of a new bifunctional NODA for bioconjugation with PSMA ligand and one-step Al18F labeling
WO2012094334A1 (en) One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
KR102015355B1 (ko) 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
US20240327464A1 (en) Peptide ligand targeting carbonic anhydrase ix, peptide construct comprising same, and uses thereof
PL239934B1 (pl) Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
JP2020524175A5 (https=)
JP7834363B2 (ja) トレーサー化合物およびその調製方法
KR101375639B1 (ko) 아미노시클로펜탄카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｐｅｔ 조영제
BR112019027183B1 (pt) Composição farmacêutica para tratar ou diagnosticar câncer de próstata, radiofármaco para diagnóstico por imageamento de câncer de próstata
KR20250127541A (ko) 방사성 동위원소가 표지된 할로겐화 벤즈아마이드 유도체 화합물을 유효성분으로 포함하는 암의 진단 또는 치료용 조성물
HK40099290A (zh) 配体及其用途

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000